These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35831249)

  • 1. Qing-Dai for pediatric ulcerative colitis multicenter survey and systematic review.
    Kudo T; Jimbo K; Shimizu H; Iwama I; Ishige T; Mizuochi T; Arai K; Kumagai H; Uchida K; Abukawa D; Shimizu T
    Pediatr Int; 2022 Jan; 64(1):e15113. PubMed ID: 35831249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis: A Single-Center Open-Label Prospective Study.
    Sugimoto S; Naganuma M; Kiyohara H; Arai M; Ono K; Mori K; Saigusa K; Nanki K; Takeshita K; Takeshita T; Mutaguchi M; Mizuno S; Bessho R; Nakazato Y; Hisamatsu T; Inoue N; Ogata H; Iwao Y; Kanai T
    Digestion; 2016; 93(3):193-201. PubMed ID: 26959688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of pulmonary arterial hypertension following long-term Qing-Dai use for ulcerative colitis.
    Inoue Y; Ishihara A; Mori T; Horio S; Yoshizane T; Arai M; Noda T
    J Cardiol Cases; 2023 May; 27(5):218-221. PubMed ID: 37180221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis.
    Suzuki H; Kaneko T; Mizokami Y; Narasaka T; Endo S; Matsui H; Yanaka A; Hirayama A; Hyodo I
    World J Gastroenterol; 2013 May; 19(17):2718-22. PubMed ID: 23674882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatically Improved Severe Pulmonary Arterial Hypertension Caused by Qing-Dai (Chinese Herbal Drug) for Ulcerative Colitis.
    Kubota K; Imai Y; Okuyama T; Ishiyama Y; Ueno S; Kario K
    Int Heart J; 2023; 64(2):316-320. PubMed ID: 37005323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colitis with wall thickening and edematous changes during oral administration of the powdered form of Qing-dai in patients with ulcerative colitis: a report of two cases.
    Kondo S; Araki T; Okita Y; Yamamoto A; Hamada Y; Katsurahara M; Horiki N; Nakamura M; Shimoyama T; Yamamoto T; Takei Y; Kusunoki M
    Clin J Gastroenterol; 2018 Aug; 11(4):268-272. PubMed ID: 29549501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indigo naturalis (Qing dai) for inflammatory bowel disease: A systematic review and meta-analysis.
    Kakdiya R; Jha DK; Choudhury A; Jena A; Sharma V
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102250. PubMed ID: 38006941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
    Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T;
    Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese herbal medicine Qing-Dai-induced pulmonary arterial hypertension in a patient with ulcerative colitis: A case report and experimental investigation.
    Sato K; Ohira H; Horinouchi T; Nakaya T; Mazaki Y; Sugimoto A; Watanabe T; Tsujino I; Nishimura M
    Respir Med Case Rep; 2019; 26():265-269. PubMed ID: 30815357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of curcumin/Qing Dai combination in children with active ulcerative colitis: a multicenter retrospective cohort study.
    Nachum NL; Salomon N; Yerushalmy-Feler A; Weintraub Y; Yogev D; Granot M; Haberman Y; Ben-Horin S; Weiss B
    Front Pediatr; 2024; 12():1342656. PubMed ID: 39403348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pulse steroid therapy in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease.
    Nagata S; Shimizu T; Kudo T; Tomomasa T; Tajiri H; Yoden A; Kagimoto S; Tahara T; Ushijima K; Uchida K; Kobayashi A
    Digestion; 2010; 81(3):188-92. PubMed ID: 20090334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Pulmonary Arterial Hypertension in a Patient Treated with Qing-Dai (Chinese Herbal Medicine).
    Misumi K; Ogo T; Ueda J; Tsuji A; Fukui S; Konagai N; Asano R; Yasuda S
    Intern Med; 2019 Feb; 58(3):395-399. PubMed ID: 30210129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Oral Qing-Dai Medication on Pulmonary Arterial Pressure Levels in Patients With Ulcerative Colitis.
    Orihara Y; Asakura M; Hida N; Kawai M; Sato T; Nishimura K; Masai K; Matsumoto Y; Okuhara Y; Goda A; Masuyama T; Nakamura S; Ishihara M
    Circ J; 2020 Jul; 84(8):1339-1345. PubMed ID: 32595175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term and long-term outcomes of indigo naturalis treatment for inflammatory bowel disease.
    Matsuno Y; Hirano A; Torisu T; Okamoto Y; Fuyuno Y; Fujioka S; Umeno J; Moriyama T; Nagai S; Hori Y; Fujiwara M; Kitazono T; Esaki M
    J Gastroenterol Hepatol; 2020 Mar; 35(3):412-417. PubMed ID: 31389626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.
    Hiwatashi N; Suzuki Y; Mitsuyama K; Munakata A; Hibi T
    J Gastroenterol; 2011 Jan; 46(1):46-56. PubMed ID: 20878425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Arai K; Kagimoto S; Kunisaki R; Hida N; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    BMC Pediatr; 2019 Oct; 19(1):351. PubMed ID: 31607268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
    Shen Z; Zheng K; Zou J; Gu P; Xing J; Zhang L; Zhu L; Shen H
    Trials; 2021 Jan; 22(1):55. PubMed ID: 33441157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.